Evidence map›Paper›PMID 23260012›Full record

ArticleBMC genomics2012

Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

Ina Schulte, Elizabeth M Batty, Jessica C M Pole, Katherine A Blood, Steven Mo, Susanna L Cooke, Charlotte Ng, Kevin L Howe, Suet-Feung Chin, James D Brenton and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A primary rectal neoplasm with novel DDX5-TFEB fusion.Virchows Archiv : an international journal of pathology · 2022
    Article
  9. Article
  10. Fixing the GAP: The role of RhoGAPs in cancer.European journal of cell biology · 2022
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. The Diverse Roles of TAO Kinases in Health and Diseases.International journal of molecular sciences · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Ina SchulteHutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK.
Elizabeth M Batty
Jessica C M Pole
Katherine A Blood
Steven Mo
Susanna L Cooke
Charlotte Ng
Kevin L Howe
Suet-Feung Chin
James D Brenton
Carlos Caldas
Karen D Howarth
Paul A W Edwards
University of Cambridge · GBHutchison/MRC Research Centre · GBCancer Research UK · GB

Funding

Breast Cancer Now 2008NOVPR21Cancer Research UK 14545Cancer Research UK 15601
6 · The paper itself

Abstract

backgroundIt has recently emerged that common epithelial cancers such as breast cancers have fusion genes like those in leukaemias. In a representative breast cancer cell line, ZR-75-30, we searched for fusion genes, by analysing genome rearrangements.

resultsWe first analysed rearrangements of the ZR-75-30 genome, to around 10kb resolution, by molecular cytogenetic approaches, combining array painting and array CGH. We then compared this map with genomic junctions determined by paired-end sequencing. Most of the breakpoints found by array painting and array CGH were identified in the paired end sequencing-55% of the unamplified breakpoints and 97% of the amplified breakpoints (as these are represented by more sequence reads). From this analysis we identified 9 expressed fusion genes: APPBP2-PHF20L1, BCAS3-HOXB9, COL14A1-SKAP1, TAOK1-PCGF2, TIAM1-NRIP1, TIMM23-ARHGAP32, TRPS1-LASP1, USP32-CCDC49 and ZMYM4-OPRD1. We also determined the genomic junctions of a further three expressed fusion genes that had been described by others, BCAS3-ERBB2, DDX5-DEPDC6/DEPTOR and PLEC1-ENPP2. Of this total of 12 expressed fusion genes, 9 were in the coamplification. Due to the sensitivity of the technologies used, we estimate these 12 fusion genes to be around two-thirds of the true total. Many of the fusions seem likely to be driver mutations. For example, PHF20L1, BCAS3, TAOK1, PCGF2, and TRPS1 are fused in other breast cancers. HOXB9 and PHF20L1 are members of gene families that are fused in other neoplasms. Several of the other genes are relevant to cancer-in addition to ERBB2, SKAP1 is an adaptor for Src, DEPTOR regulates the mTOR pathway and NRIP1 is an estrogen-receptor coregulator.

conclusionsThis is the first structural analysis of a breast cancer genome that combines classical molecular cytogenetic approaches with sequencing. Paired-end sequencing was able to detect almost all breakpoints, where there was adequate read depth. It supports the view that gene breakage and gene fusion are important classes of mutation in breast cancer, with a typical breast cancer expressing many fusion genes.

Indexed as

Base SequenceBreast NeoplasmsCell Line, TumorChromosome MappingCloning, MolecularComparative Genomic HybridizationFemaleGenome, HumanHumansMolecular Sequence DataOncogene Proteins, FusionSequence AlignmentSequence Analysis, DNAOncogene Proteins, Fusion

Identifiers

PMID23260012
PMCPMC3548764
OpenAlexW2047775319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.